![Intersect ENT's investigational steroid eluting implant](http://www.globenewswire.com/en/Attachment/LogoDisplay/311692?filename=311692.jpg&size=2)
Photo Release -- Intersect ENT Announces Positive Data From Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis
September 22, 2014 08:25 ET
|
Intersect ENT
MENLO PARK, Calif. and Orlando, Fla., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat...
![Intersect ENT Logo](/news-release/logo/305685/0/305685.jpg?lastModified=12%2F09%2F2016%2023%3A36%3A07&size=2)
Intersect ENT Enrolls First Patient in Clinical Study to Expand Access to PROPEL Treatment to Broader Patient Population
September 17, 2014 17:58 ET
|
Intersect ENT
MENLO PARK, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today...
![Intersect ENT Logo](/news-release/logo/305685/0/305685.jpg?lastModified=12%2F09%2F2016%2023%3A36%3A07&size=2)
Intersect ENT Reports Second Quarter 2014 Results
September 03, 2014 16:01 ET
|
Intersect ENT
MENLO PARK, Calif., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today...
![Intersect ENT Logo](/news-release/logo/305685/0/305685.jpg?lastModified=12%2F09%2F2016%2023%3A36%3A07&size=2)
Intersect ENT to Announce Second Quarter Financial Results
August 22, 2014 08:05 ET
|
Intersect ENT
MENLO PARK, Calif., Aug. 22, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today...
![Intersect ENT Logo](/news-release/logo/305685/0/305685.jpg?lastModified=12%2F09%2F2016%2023%3A36%3A07&size=2)
Study Indicates Cost Effectiveness of Intersect ENT's PROPEL Implant for Chronic Sinusitis
August 11, 2014 08:05 ET
|
Intersect ENT
MENLO PARK, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today...
![Intersect ENT Logo](/news-release/logo/305685/0/305685.jpg?lastModified=12%2F09%2F2016%2023%3A36%3A07&size=2)
Intersect ENT Announces Closing of its Initial Public Offering
July 29, 2014 16:05 ET
|
Intersect ENT
MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and...
![Intersect ENT Logo](/news-release/logo/305685/0/305685.jpg?lastModified=12%2F09%2F2016%2023%3A36%3A07&size=2)
Intersect ENT Announces Pricing of Its Initial Public Offering
July 24, 2014 08:05 ET
|
Intersect ENT
MENLO PARK, Calif., July 24, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc., a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat...